RFS
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kazuki Nozawa, Masataka Sawaki, Yukari Uemura, Michiko Tsuneizumi, Toshimi Takano, Naomi Gondo, Fumikata Hara, Michiko Harao, Tatsuya Toyama, Naruto Taira, Ana Vivancos, Charles M Perou, Esther Sanfeliu, Fara Brasó-Maristany, Joel S Parker, Wesley Buckingham, Laia Paré, Guillermo Villacampa, Mercedes Marín-Aguilera, Patricia Villagrasa, Aleix Prat, Hiroji Iwata
Nat Commun 16(1) 9585
Older adults with HER2-positive early breast cancer are underrepresented in clinical trials, and the benefit of chemotherapy in this population remains uncertain. We evaluated the HER2DX genomic assay within the randomized RESPECT trial (NCT01104935), which compared adjuvant trastuzumab with or without chemotherapy in patients aged 70-80 years. In this prespecified translational analysis (Trans-RESPECT), HER2DX scores were available for 154 patients. The HER2DX risk score classified 74.0% as low risk and 26.0% as high risk. Ten-year relapse-free and overall survival were higher in the low-risk group. HER2DX remained independently associated with overall survival in multivariable analysis. The HER2DX immune, luminal, and proliferation signatures that compose the risk score were also prognostic. While the HER2DX pCR score was not prognostic overall, exploratory subgroup analyses suggested a potential survival benefit from chemotherapy in the pCR-high group. HER2DX offers prognostic value and may guide chemotherapy use in older patients with HER2-positive early breast cancer. Clinical Trial Information NCT01104935.
3 个 Figure · 10 个 KM 面板
Fig. 1. Prognostic value of the HER2DX risk score for long-term outcomes. A Kaplan–Meier curve for RFS according to HER2DX risk group (low vs high) in all patients. B Kaplan–Meier curve for OS according to HER2DX risk group in all patients. C RFS by HER2DX risk group in the node-negative subgroup. D OS by HER2DX risk group in the node-negative subgroup. Hazard ratios (HRs), 95% confidence intervals (CIs), and p -values were calculated using Cox proportional hazards models. The HER2DX risk score was applied using prespecified cutoffs.
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel B
Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel C
Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel D
Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2. Prognostic value of individual HER2DX biological signatures and composite score. A Heatmap of percentile scores for immune, luminal, and proliferation signatures across 154 tumors profiled in Trans-RESPECT, illustrating biological heterogeneity. Correlation coefficients (r) between two signatures are shown below the heatmap. In addition, HER2DX risk scores are shown for each patient. B Table showing hazard ratios (HRs) for RFS and OS across the three HER2DX biological signatures, immune/IGG, luminal, and proliferation, and TILs evaluated in the full cohort and in the node-negative subgroup. Sensitivity analyses are shown using different censoring timepoints (5–10 years and uncensored [U*]). Favorable HRs (below 1.0) are highlighted in green, while unfavorable HRs (above 1.0) are in red. C Kaplan–Meier curve showing 10-year RFS by composite score (0 to 3 favorable biological signatures). D Kaplan–Meier curve showing 10-year OS by composite score. The composite score assigns one point for each favorable feature: immune-high, luminal-high, and proliferation-low. E Boxplots showing the association between TIL levels and each HER2DX biological signature (IGG/immune, luminal, proliferation). P values are derived from Kruskal–Wallis tests.
Fig. 2 · Panel C
Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel D
Panel D 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3. Chemotherapy benefit according to HER2DX pCR likelihood score. A Kaplan–Meier curves for RFS by treatment arm (trastuzumab alone vs trastuzumab + chemotherapy) in HER2DX pCR-high tumors. B Kaplan–Meier curves for OS by treatment arm in HER2DX pCR-high tumors. C RFS by treatment arm in HER2DX pCR-medium/low tumors. D OS by treatment arm in HER2DX pCR-medium/low tumors. Hazard ratios, 95% CIs, and p -values were derived from univariable Cox models. Interaction p -values reflect formal tests for treatment–biomarker interaction.
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel B
Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel C
Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D
Panel D 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。